A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMORS (XL092-311 (STELLAR-311))

Principal Investigator

Jaseela Chiramel

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1011801